ReviewJournal of inflammation research2025
Purinergic Receptors in Dendritic Cells.
Review in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study.Journal of translational medicine · 2026Trial
- Metabolic remodeling by circular RNAs in gastric tumorigenesis: From mechanisms to biomarker discovery (Review).International journal of oncology · 2026Review
- P2X7 Receptor in Rare Diseases: Shared Molecular Mechanisms and Therapeutic Implications.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) are regarded as highly effective antigen-presenting cells (APCs) and play a crucial role in immunomodulation. A growing body of research focuses on extracellular purines and their purinergic receptors in DCs. In this review, we provide an overview of the expression and function of purinergic receptors (P1 and P2) in DCs. To date, four P1 receptors (A1, A2A, A2B, A3), five P2X receptors (P2X1, P2X4, P2X5, P2X6, P2X7) and eight P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, P2Y14) have been reported to be expressed in DCs, with expression levels varying according to DC developmental stages (immature vs mature) and subsets. Functionally, P1 receptors are preferentially activated by adenosine(ADO) generated via ectonucleotidases, promoting the release of cytokines such as IL-10 and IL-23, and enhancing the activation, migration, and antigen presentation of DCs. In contrast, extracellular ATP-activated P2 receptors increase the secretion of pro-inflammatory cytokines including TNF-α, IL-1β, IL-18, and IL-12, while simultaneously inhibiting DC migration and antigen presentation efficiency. Therefore, only under the conditions that immune cells express the relevant receptors and ectonucleotidases dynamically regulate the ATP/ADO ratio can a mutually restrictive Yin-Yang relationship between P1 and P2 receptors be established, thereby safeguarding systemic immune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.